期刊
JOURNAL OF INTERNAL MEDICINE
卷 286, 期 1, 页码 32-40出版社
WILEY
DOI: 10.1111/joim.12892
关键词
dysbiosis; gut-liver axis; metabolome; tryptophan
资金
- Erwin Schrodinger Fellowship from the Austrian Science Fund [J4063]
- NIH [R01 AA020703, R01 AA24726, U01 AA021856]
- Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [I01BX002213]
- Austrian Science Fund (FWF) [J4063] Funding Source: Austrian Science Fund (FWF)
Alterations in the bacteria that reside in our gastrointestinal tract play a role in the pathogenesis and progression of many disorders including liver and gastrointestinal diseases. Both qualitative (composition) and quantitative (amount) changes in gut microbes are associated with increased susceptibility to liver disease. Importantly, the intestinal microbiota is involved in the regulation of many host signalling pathways via the generation of different metabolites. Hence, dysbiosis influences disease development and progression by directly affecting the host-bacteria metabolic interaction. Microbe-derived harmful metabolites can translocate to distant organs due to increased intestinal permeability as observed during dysbiosis. Contrary, certain bacterial metabolites such as tryptophan metabolites contribute to intestinal and systemic homeostasis. Here, we provide an overview of current evidence describing to what extent microbial metabolites modulate the development of chronic liver diseases such as alcoholic steatohepatitis and nonalcoholic fatty liver disease with a special emphasis on indoles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据